Members
The ECICC is supported by groups of experts composed of physicians, epidemiologists, researchers and patients/caregivers. All group members join the initiative on a voluntary basis after selection through a transparent process following a public call launched in 2021.
Professional and patient and/or caregiver experts act in their personal capacity, independently and in the public interest. They do not represent any private, commercial or national interests. To ensure this, in addition to their official declarations of confidentiality and commitment, all experts submit an annual declaration of interests relevant to the initiative.
The ECICC is supported by the following groups:
- a working group – the decision-making body that finalises recommendations and requirements proposed by topic-specific groups,
- topic-specific groups – temporary groups that develop evidence-based proposals for recommendations regarding specific healthcare questions and for quality requirements, supported by independent experts who conduct systematic reviews. The proposals are reviewed by the working group, after which the topic-specific groups are dissolved.
Working group
Former Members
Topic-specific groups
Ongoing
FIT threshold recommendations
| Duration | Members |
| April 2025 - Present | Spaander Manon (Co-lead) Carlo Senore (Co-lead) Marc Thelen (Co-lead) Hikmet Can Cubukcu Silvia Deandrea Cristina Maraldi Garcia Montse Mauro Panteghini |
Invitation strategies recommendations
| Duration | Members |
|---|---|
| March 2024 - Present | Paolo Giorgi Rossi (Co-lead) Amir Qaseem (Co-lead) Stefan Gijssels Livia Giordano Heather Lynn Rogers Zuleika Saz Parkinson Alan Smith |
Marker states recommendations
| Duration | Members |
|---|---|
| November 2022 - Present | Tejan Baldeh (Co-lead) Zuleika Saz Parkinson (Co-lead) Mario Dinis Ribeiro Audrius Dulskas Stefan Gijssels Ullrich Graeven Maria Hass Margarita Posso |
Pre-malignant lesions recommendations
| Duration | Members |
| October 2025 - Present | Mario Dinis Ribeiro (Co-lead) Antonino Spinelli (Co-lead) Darco Babic Audrius Dulskas Ullrich Graeven Rodrigo Jover Martinez Cristina Maraldi Zorana Maravic Iris Nagtegaal Mori Yuichi |
Quality indicator evidence
| Duration | Members |
| October 2023 - Present | Thomas Pigott (Co-lead) Holger Schunemann (Co-lead) Ullrich Graeven Miranda Langendam Elena Parmelli |
Screening age-ranges recommendations
| Duration | Members |
|---|---|
| November 2022 - Present | Holger J. Schünemann (Co-lead) Carlo Senore (Co-lead) Shahnaz Sultan (Co-lead) Amanda Drury Rodrigo Jover Martinez Miranda Langendam Iris-Lansdorp-Vogelaar Zorana Maravic Isabel Portillo Monique van Leerdam Nancy van Damme |
Screening and diagnosis requirements
| Duration | Members |
|---|---|
| August 2022 - Present | Miriam Cuatrecasas (Co-lead) Rodrigo Jover Martinez (Co-lead) Joaquin Cubiella Silvia DeAndrea Evelin Dekker Elefftheriadis Eleftherios Carlo Senore Marc Thelen Marcis Leja Mauro Panteghini |
Screening tests recommendations
| Duration | Members |
| February 2025 - Present | Holger Schunemann (Co-lead) Carlo Senore (Co-lead) Shahnaz Sultan (Co-lead) Amanda Drury Rodrigo Jover Martinez Miranda Langendam Iris Lansdorp-Vogelaar Monique van Leerdam Nancy van Damme Zorana Maravic Isabel Portillo Paolo Giorgi Rossi Zuleika Saz-Parkinson |
Supportive care (across initiatives)
| Duration | Members |
| November 2025 - Present | Pierfrancesco Franco (Co-lead) Csaba Laszlo Degi (Co-lead) Mirjana Babamova Margarida Brito Goncalves Kimon Chatzistamatiou Amanda Drury Marcos Gomez Ruiz Pierre Martin Hirsch Helen Kelly Allesandro Laviano Hugo Ribeiro Grainne Sheill Eva-Maria Stromsholm Andrea Stupalova Piret Veerus |
Treatment requirements
| Duration | Members |
| May 2025 - Present | Ullrich Graeven (Co-lead) Laurents Stassen (Co-lead) Miriam Cuatrecasas Audrius Dulksas Amanda Drury Pierfrancesco Franco Maria Hass Thomas Helmberger Stefanie Hegenberg Kostantinos-Velios Kamposioras Frank Kolligs |
Closed
Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs recommendations
| Duration | Members |
|---|---|
| Closed | Francesco Sclafani (Co-lead) Shaukat Aasma (Co-lead) Michael Hoffmeister Holger J. Schünemann Iris Lansdorp-Vogelaar Bala Malgorzata Luigi Ricciardiello Heather Lynn Rogers Zuleika Saz Parkinson Gijssels Stefan |
Background overviews recommendations
| Duration | Members |
|---|---|
| Closed | Ullrich Graeven (Co-lead) Samer Karam (Co-lead) Iris Lansdorp-Vogelaar Holger J. Schünemann Paolo Giorgi Rossi Zuleika Saz Parkinson Shahnaz Sultan |
Certification requirements
| Duration | Members |
|---|---|
| Closed | Isabel Portillo (Co-lead) Carlo Senore (Co-lead) Mario Dinis Ribeiro Silvia DeAndrea Montserrat Garcia Iris Lansdorp-Vogelaar |
General requirements
| Duration | Members |
|---|---|
| Closed | Ullrich Graeven (Co-lead) Degi Laszlo Csaba (Co-lead) Zorana Maravic Nancy van Damme Audrius Dulskas Amanda Drury Marianne Grønlie Guren Michael Hoffmeister Stefanie Nöpel-Dünnebacke Laurents Stassen |
Healthy lifestyles recommendations
| Duration | Members |
|---|---|
| Closed | Livia Giordano (Co-lead) Zuleika Saz Parkinson (Co-lead) Ioanna Bakogianni Maria Haas Singh Harminder Holger J. Schünemann Magdalena Stepien |
Micronutrients recommendations
| Duration | Members |
| Closed | Malgorzata Bala (Co-lead) Amanda Drury (Co-lead) Aurora Perez Cornago Livia Giordano Zorana Maravic Shahnaz Sultan |
Meetings
Both the working group (the decision-making body) and the active topic-specific groups (typically composed by selected working group and expert pool members) meet regularly online at least every month to discuss and decide on recommendations or requirements. In addition, the working group convenes in-person at least once a year to discuss and decide on recommendations and requirements.
- June 2026Working Group
Decision on the complete set of requirements for Fecal Immunochemical Test, on two requirements for pathology and discussion on management of premalignant lesions, FIT thresholds, and colonoscopic surveillance post-adenoma removal.
- November 2025Working Group
Decision on the Fecal Immunochemical Test requirements, aspirin and micronutrient recommendations and quality indicators to monitor screening recommendations
- June 2025Working group
Discussion on the monitoring quality indicators for screening age-ranges recommendations
- November 2024Working group
Decision on the general requirements worksheets (GEN3-GEN7) to be considered for the European quality assurance scheme for colorectal cancer services
- June 2024Working group
Discussion on screening tests and quality assurance requirements
- May 2024Working group
Decision on the general requirements worksheets (GEN1-GEN2) to be considered for the European quality assurance scheme for Colorectal Cancer Services.
Discussion on screening age ranges and screening tests. - March 2024Working group
Discussion on aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) for primary prevention of colorectal cancer in average risk adults, as well as on screening age ranges
- December 2023Working group
Discussion on aspirin and non-aspirin NSAIDs for primary prevention of colorectal cancer in average risk adults
- October 2023Working group
Information session on quality assurance
- September 2023Working group
Decision on good practice statements for minimising alcohol consumption, not smoking, regular physical activity, and counselling on healthy lifestyles to prevent colorectal cancer and its recurrence
- June 2023Working group
Discussion on outcome prioritisation and marker states development. Other discussed topics: decision thresholds on desirable and undesirable effects, screening age ranges and quality indicators
- March 2023Working group
Decision on marker states: approval and prioritisation
- January 2023Working group
Decision on certification requirements of the European quality assurance scheme for colorectal cancer services
- November 2022Working group
Prioritisation of the healthcare questions to be included in European guidelines on colorectal cancer primary prevention and screening
- June 2022Working group
Kick-off meeting